Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

The F.D.A. ordered compounding for versions of Eli Lilly’s Zepbound to end last month. Small compounders have until April 22 to stop making and selling versions of Novo Nordisk’s Wegovy ...

Some of the more than a dozen states that cover GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid are scrambling ...

As an obesity treatment, Wegovy, made by Novo Nordisk, comes with a slightly higher dose for treating obesity than doses for diabetes; the medication is otherwise the same. For Zepbound ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs ...

Medications targeting weight loss like Wegovy and Zepbound are part of a relatively new class of drugs that work by suppressing appetite and food intake. They’ve been hailed as not only life ...

Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift Monday, after a potential competitor decided to cancel development of its GLP-1 obesity drug. “We continue ...

That was music to the ears of investors in Novo Nordisk, which makes diabetes and obesity treatments Ozempic and Wegovy; and in Eli Lilly, which makes Mounjaro and Zepbound diabetes and obesity drugs.